The stock of Coherus Biosciences Inc (NASDAQ:CHRS) is a huge mover today! About 230,281 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 58.72% since March 16, 2016 and is uptrending. It has outperformed by 53.17% the S&P500.
The move comes after 6 months positive chart setup for the $1.33 billion company. It was reported on Oct, 19 by Barchart.com. We have $39.71 PT which if reached, will make NASDAQ:CHRS worth $412.30M more.
Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on November, 14. They expect $-1.71 earnings per share, up 8.06% or $0.15 from last year’s $-1.86 per share. After $-1.72 actual earnings per share reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -0.58% EPS growth.
Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage
Out of 6 analysts covering Coherus Biosciences (NASDAQ:CHRS), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Coherus Biosciences has been the topic of 6 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Citigroup given on Wednesday, July 27. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) has “Outperform” rating given on Wednesday, October 19 by Robert W. Baird. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) earned “Overweight” rating by Barclays Capital on Monday, November 23. The firm has “Buy” rating given on Wednesday, September 7 by Maxim Group. Zacks upgraded the stock to “Hold” rating in Thursday, September 3 report. The firm earned “Outperform” rating on Wednesday, January 20 by Credit Suisse.
According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”
Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.99, from 1.33 in 2016Q1. The ratio improved, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.
New York State Common Retirement Fund has 30,200 shares for 0% of their US portfolio. Kohlberg Kravis Roberts Communications Limited Partnership has invested 0.54% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Citigroup reported 17,433 shares or 0% of all its holdings. Macquarie Grp Inc Ltd holds 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS) for 55,555 shares. Deutsche Bank Ag, a Germany-based fund reported 46,792 shares. Nationwide Fund Advsrs last reported 36,445 shares in the company. Voya Inv Mgmt Llc last reported 0% of its portfolio in the stock. The New York-based Savings Bank Of New York Mellon Corp has invested 0% in Coherus Biosciences Inc (NASDAQ:CHRS). Turner Invests L P accumulated 0.64% or 120,850 shares. Fmr Limited Com has invested 0.01% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Birchview Lp accumulated 0.09% or 7,500 shares. Strs Ohio holds 600 shares or 0% of its portfolio. Jacobs Levy Equity Management Inc has 0% invested in the company for 12,800 shares. Eventide Asset Mngmt Ltd holds 0.15% or 145,000 shares in its portfolio. Millennium Mgmt Ltd accumulated 400,940 shares or 0.02% of the stock.
More notable recent Coherus Biosciences Inc (NASDAQ:CHRS) news were published by: Benzinga.com which released: “Here’s Why Coherus BioSciences Is An Underappreciated Biosimilar Pure Play” on October 19, 2016, also Globenewswire.com with their article: “Coherus BioSciences Regains Development and Commercial Rights to CHS-0214 From …” published on September 27, 2016, Globenewswire.com published: “Coherus BioSciences Management to Present at Two Investor Healthcare …” on September 01, 2016. More interesting news about Coherus Biosciences Inc (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results” published on August 09, 2016 as well as Globenewswire.com‘s news article titled: “Coherus BioSciences Appoints Patrick O’Brien as Senior Vice President …” with publication date: May 16, 2016.
CHRS Company Profile
Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.